Podcasts about rituxan

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Susan Desmond-Hellmann is a physician and scientist whose remarkable career has spanned clinical medicine, oncology, biotech innovation, and global health leadership. In this episode, Susan shares insights from her journey training in internal medicine during the early AIDS crisis, treating HIV-related cancers in Uganda, and developing groundbreaking cancer therapies like Herceptin and Avastin. She reflects on her leadership roles at UCSF and the Bill and Melinda Gates Foundation, offering lessons on guiding large-scale health initiatives, navigating uncertainty, and fostering scientific innovation. The conversation explores the promise of precision medicine, the integration of patient care and policy, and the evolving role of artificial intelligence in transforming diagnostics, drug development, and global access to care. We discuss: Susan's medical training, the start of the AIDS epidemic, and the transformative experiences that shaped her career [3:00]; Susan's experience working on the frontlines of the HIV/AIDS crisis in Uganda [12:30]; Susan's time working in general oncology and her transition to biotech where she helped develop taxol—a top-selling cancer drug [26:30]; Genentech's origins, and its groundbreaking use of recombinant DNA to develop biologic drugs [33:45]; Susan's move to Genentech, and her pivotal role in the development and success of Herceptin as a groundbreaking therapy in targeted oncology [44:00]; The rise of antibody-based cancer therapies: the development of Rituxan and Avastin [52:15]; The step-by-step drug development process and the scientific and strategic challenges involved [1:01:30]; The ethical and economic controversy surrounding Avastin's high cost and limited survival benefit [1:12:30]; Susan's tenure as chancellor at UCSF: leading during a financially strained period, and her strategic approach to fundraising and institutional development [1:14:45]; What Susan learned as CEO of the Bill and Melinda Gates Foundation: strategic processes and decision-making frameworks [1:26:00]; Susan's philosophy of leadership and how she sought to build an empowering, values-driven culture at the Gates Foundation [1:35:15]; The erosion of public trust in science during COVID, the communication failures around controversial treatments like ivermectin, and the need for better public health engagement and transparency [1:39:30]; The role of AI in transforming medicine: from drug development to cancer detection and beyond [1:53:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Die Auswertung vieler Studien weltweit hat gezeigt, das die Basistherapie das beste Mittel gegen das Voranschreiten der MS ist. Du kannst den Beitrag auf meinem Blog Nachlesen: https://ms-perspektive.de/podcast-005-die-basistherapie Der folgende Beitrag ist ein Update zu Folge 5, in der es um die Basistherapie geht, ergänzt um meine Erkenntnisse aus den vergangenen fünf Jahren und meinem Multiple Sklerose Management Studium. Die Bedeutung der Immuntherapie ist heute klarer denn je: Sie kann das Fortschreiten der MS verlangsamen und mögliche Einschränkungen hinauszögern. In diesem Beitrag teile ich aktuelle wissenschaftliche Erkenntnisse, neue Therapieoptionen und meine persönlichen Erfahrungen. Zudem erfährst du, warum eine frühzeitige Basistherapie so wichtig ist und welche Entwicklungen es in der MS-Forschung gibt. Inhaltsverzeichnis Update zur Basistherapie Fortschritte in der Forschung Bedeutung der Präzisionsmedizin Einführung in die Basistherapie Rückblick auf persönliche Erfahrungen Empfehlungen zur sofortigen Therapie Der Weg mit meiner Basistherapie Schwangerschaft und Therapieanpassungen Anpassung der Therapie Buchveröffentlichung und weitere Informationen Medikamente und deren Wirksamkeit Überwinde deine Ängste vor der Basistherapie! Wichtige Erkenntnis zur MS und der neurologischen Reserve Zukunftsaussichten: Hoffnung auf Remyelinisierung Plädoyer für die Basistherapie Zusammenfassung – Die wichtigsten Punkte auf einen Blick: Mein persönliches Fazit: Weiterführende Infos zur Immuntherapie Mein persönliches Fazit: Das war heute mein dringendes Plädoyer für die Basistherapie. Ich wünsche dir, mir und allen anderen da draußen viel Gesundheit, viel Kraft und eine möglichst lange Zeit ohne Einschränkungen.

Erfahre mehr über B-Zell-Depletionen, wie Ocrevus, Kesimpta, Bonspri, Mabthera, Rituxan und Briumvi, für aktive RRMS & SPMS und frühe PPMS. Du kannst den vollständigen Beitrag auf meinem Blog nachlesen: https://ms-perspektive.de/274-b-zell-depletion B-Zell-Depletions-Therapien wie Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan) und Ublituximab (Briumvi) sind zu wichtigen Instrumenten bei der Behandlung von Multipler Sklerose (MS) geworden. Diese Behandlungen zielen speziell auf B-Zellen ab, eine Art von Immunzellen, die am Entzündungsprozess von MS beteiligt sind, und reduzieren diese. B-Zell-Therapien gelten als einige der spezifischsten und wirksamsten verlaufsmodifizierenden Therapien, die heute verfügbar sind, und bieten einen maßgeschneiderten Ansatz zur Verringerung der Krankheitsaktivität und des Fortschreitens der MS. In diesem Beitrag geht es darum, wie diese Therapien innerhalb der MS-Behandlungsoptionen eingeordnet werden und was ihr Zulassungsstatus und ihre Wirksamkeit für verschiedene Patientengruppen bedeuten. Bitte beachte, dass ich hier nur einen Überblick geben kann. Deine Neurologin und MS-Schwester sollten dich ausführlich über die richtige Therapie für dich beraten. Sie kennen deinen allgemeinen Gesundheitszustand und du solltest auch über deine Ziele, Wünsche, Ängste und Vorlieben sprechen, damit diese berücksichtigt werden können. Inhaltsverzeichnis Allgemeine Informationen Wie werden B-Zell-Depletionen - Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) in den Immuntherapien eingeordnet? Wofür sind B-Zell-Depletionen - Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) zugelassen? Wie sieht die Situation für spezielle Patientengruppen aus? Wer sollte Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) vermeiden? Wie wirken Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan) und Ublituximab (Briumvi)? Wie wird es eingenommen? Wie wirksam sind Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi)? Risiken und Nebenwirkungen von Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) Impfungen Quellen Schlussbemerkung Quellen Für die Erstellung des Inhalts habe ich folgende Quellen verwendet: Vorlesung über pädiatrische Multiple Sklerose von Prof. Dr. Jutta Gärtner im Rahmen des Masterstudiengangs Multiple-Sklerose-Management Vorlesung über B-Zell-depletierende Therapien von Prof. Dr. Xavier Montalban im Rahmen des Masterstudiengangs Multiple-Sklerose-Management Qualitätshandbuch der KKNMS zu Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Ublituximab (Briumvi) MS-Selfie-Infokarten von Prof. Dr. Gavin Giovannoni Deutschsprachiges Multiple Sklerose und Kinderwunschregister (DMSKW) Deutsche DECIMS-Informationen zu Ocrelizumab --- Vielleicht möchtest du auch einen Blick auf die Beiträge zu den anderen Immuntherapien werfen: #256: Dimethylfumarat (Tecfidera) und Diroximelfumarat (Vumerity) #258: Glatirameracetat (Copaxone, Brabio) #261: Interferon-beta (Avonex, Betaferon, Extavia, Plegridy, Rebif) #264: Teriflunomid (Aubagio) #266: Natalizumab (Tysabri, Tyruko)  #268: S1P-Modulatoren – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) #270: Alemtuzumab (Lemtrada, Campath) bei hochaktiver Multipler Sklerose #272: Cladribin (Mavenclad, Leustatin, Litak) bei hochaktiver MS Bis bald und mach das Beste aus Deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

In this conversation, Dr. Isabelle Amigues discusses the treatment of Sjogren's syndrome. She shares several patient cases to illustrate different treatment approaches. The goal of the episode is to provide insights into how rheumatologists think when treating Sjogren's syndrome. Dr. Amigues emphasizes the importance of achieving remission and preventing further damage. She discusses the use of immunosuppressive agents, such as Plaquenil and Rituxan, based on the severity of symptoms. She also provides recommendations for managing dry eyes and dry mouth, as well as addressing fatigue and fibromyalgia symptoms. Dr. Amigues concludes by highlighting the importance of regular dental, ophthalmologist, and neurologist visits for Sjogren's syndrome patients.This episode comes from Dr. Amigues' educational YouTube channel,  Rheumatology101! Check it out and subscribe so you don't miss a new live stream every Tuesday at 11AM.________________________________________________________________________________________________Join the community and follow UnabridgedMD on social media!Instagram: @unabridgedmdFacebook: @UnabridgedMDTiktok: @unabridgedmdIf you live in Colorado and are looking for a rheumatologist to help you achieve disease remission, email or contact us at UnabridgedMD.com. We are the first direct care rheumatology in Colorado and can see you within a week!Click here to get in touch: https://www.unabridgedmd.comOr give us a call: 303-731-4006

In this episode, we chat with JR Brandt of Montana, an acute lymphocytic leukemia (ALL) survivor, about his journey through diagnosis, treatment, and living with chronic graft-versus-host disease (cGVHD). JR shares his initial diagnosis story, describing how what he thought was a minor infection led to a leukemia diagnosis complicated by the Philadelphia Positive chromosome. He underwent 26 days of chemotherapy and was eventually cleared for a bone marrow stem cell transplant at Stanford University in March 2017.JR discusses the onset of chronic GVHD symptoms about a year after his transplant, beginning with skin changes. He was treated with Rituxan infusions, which provided temporary relief. Over the years, as symptoms re-emerged, JR continued Rituxan treatments and adjusted his care plan, even after moving from California to Montana. He highlights the importance of finding and continuing care with familiar healthcare professionals, like his physician who (fortunately) moved to Billings Clinic.Beyond skin issues, JR describes experiencing joint tightness, dry eyes, dysphagia, and dry mouth. He mentions practical solutions like using Biotene toothpaste for dry mouth and preservative-free Refresh Plus eyedrops for dry eyes. JR also shares the importance of physical and occupational therapy, which helped him develop a personalized exercise routine. Over time, he transitioned to aquatic aerobics and massage therapy, finding these methods more effective for managing his symptoms.JR emphasizes the significance of staying active, despite physical limitations, by adapting activities like biking with an e-bike and engaging in water aerobics. He also discusses the importance of sun protection and practical tips for managing GVHD symptoms, like using a sun hat and sunblock.JR addresses the mental health challenges of living with chronic illness, equating his experiences to PTSD and stressing the importance of setting goals and making plans to stay motivated. He shares how maintaining an active lifestyle and staying connected with his family helps him manage anxiety and stress.When discussing his career, JR explains how his background in healthcare was both a benefit and a challenge. He advises others with disabilities to utilize vocational rehabilitation services to explore new career paths. JR also encourages being your own patient advocate, ensuring all medical information is shared among healthcare providers to provide comprehensive care.JR concludes with the importance of using available resources, like the Americans with Disabilities Act, for mobility aids and other accommodations (link below). He highlights the need for continuous learning and resourcefulness in managing chronic GVHD and living life to the fullest. Products mentioned by JR in this episode:Refresh Eye Drops: https://www.refresheyedrops.com/Biotene for Dry Mouth: https://www.biotene.com/DaBrim Helmet/SunShade: https://dabrim.com/Oofos shoes: https://www.oofos.com/Mechanix Gloves: https://www.mechanix.com/Dycem Non-Slip tape: https://www.dycem-ns.com/Tryvaya (Prescription) Nasal Spray for Dry Eye: https://www.tyrvaya.com/Full list of Vocational Rehabilitation Agencies for all 50 states: https://rsa.ed.gov/about/statesAmericans With Disabilities Act (ADA) Requirements for Power-Driven Mobility Devices: https://www.ada.gov/resources/opdmds/This season is made possible thanks to donations from Syndax and Incyte.https://syndax.com/https://incyte.com/ Follow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/

The Bill & Melinda Gates Foundation, with an endowment of over $50 billion, is one of the largest and most influential philanthropic organizations in the world. With a focus on addressing global health, poverty, and education, its initiatives have led to the reduction of malaria mortality by 60% over the past two decades, the near eradication of polio, increased educational opportunities of millions of students, and improved sanitation conditions for millions of people in developing countries. For six years, oncologist Sue Desmond-Hellmann, MD, MPH was the CEO of this organization. Prior to that, she served as Chancellor of the University of California at San Francisco, as well as President of Product Development at Genentech, where she oversaw the development of Herceptin, Avastin, Rituxan, and other blockbuster cancer drugs that are now staples in the arsenal of many medical oncologists.The topics of our discussion in this episode are as varied as Dr. Desmond-Hellman's career. We discuss, among other things, how seeing the work of her pharmacist father encouraged her to pursue a career in medicine, how her early experiences treating HIV patients in Uganda spurred her to tackle global health challenges, how she discovered a passion for product development in the pharmaceutical industry, how she reconciles the ethical quandaries of developing medications that can cause serious adverse effects and that can sometimes cost hundreds of thousands of dollars per dose, what her mission while at the Gates Foundation was, and her perspectives on the role of artificial intelligence and human health and well-being, now that she has joined the board of directors of OpenAI, the company behind ChatGPT.In this episode, you will hear about: 2:50 - How working in her father's pharmacy led Dr. Desmond-Hellmann to a career in medicine4:56 - A brief summary of Dr. Desmond-Hellmann's multifaceted career trajectory15:36 - What the day to day work of pharmaceutical drug development looks like 18:30 - The challenging ethical concerns that surround drug approvals especially as it pertains to safety concerns23:44 - Dr. Desmond-Hellmann's experiences in Uganda that forever transformed her views on poverty 27:55 - The aims of the Gates Foundation 30:47 - How Dr. Desmond-Hellmann views her work both in the non-profit and the for-profit sectors 37:15 - Dr. Desmond-Hellmann's mission when she took on a leading role at The Gates Foundation 38:38 - How Dr. Desmond-Hellmann thinks about shaping the future of AI as she takes a seat on the board of OpenAI45:14 - Dr. Desmond-Hellmann's advice for medical trainees and clinicians on how to navigate the many opportunities available to them along their career pathDr. Sue Desmond-Hellmann can be found on Twitter/X @suedhellmann.Visit our website www.TheDoctorsArt.com where you can find transcripts of all episodes.If you enjoyed this episode, please subscribe, rate, and review our show, available for free on Spotify, Apple Podcasts, or wherever you get your podcasts. If you know of a doctor, patient, or anyone working in health care who would love to explore meaning in medicine with us on the show, feel free to leave a suggestion in the comments or send an email to info@thedoctorsart.com.Copyright The Doctor's Art Podcast 2024

In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses:Optimal selection of therapy for treatment-naive CLL, including second-generation covalent BTK inhibitorsConsiderations in therapy selection for previously treated CLLNovel strategies for treating CLL Presenters:Danielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies and Cellular TherapyDuke Cancer InstituteDurham, North CarolinaBrian Hill, MD, PhDDirector, Lymphoid Malignancies ProgramStaff Physician, Department of Hematology and Medical OncologyTaussig Cancer InstituteCleveland ClinicCleveland, OhioDeborah Stephens, DOAssociate ProfessorDirector of the CLL ProgramLineberger Comprehensive Cancer CenterUniversity of North CarolinaChapel Hill, North CarolinaContent based on a live and online CME program supported by educational grants from AstraZeneca; BeiGene, Ltd.; and Lilly.Link to full program including downloadable slides: https://bit.ly/49YxtSq

Synopsis: In this episode of Biotech2050, Dr. Ted Love, former CEO of Global Blood Therapeutics and Current Chairman of BIO, shares insights on sickle cell breakthroughs, transitioning from academia to research, navigating a tight funding environment, and protecting an innovative ecosystem to benefit patients. Biography: Dr. Ted Love is the chair of the Board of Directors at the Biotechnology Innovation Organization (BIO), a position he assumed in June 2023. A long-time BIO Board Member, Dr. Love has focused on championing access to care, standing up for science, and improving the narrative around the biopharma industry. Dr. Love previously served as president and chief executive officer of Global Blood Therapeutics (GBT). During his tenure at GBT, Dr. Love led the company from a pre-clinical start-up, through the accelerated approval and launch of Oxbryta®, and into a global commercial company with an advanced pipeline of innovative therapies focused on sickle cell disease. Prior to GBT, Dr. Love was executive vice president, research and development and technical operations, at Onyx Pharmaceuticals, Inc., where he played an instrumental role in the accelerated approval of Kyprolis® for multiple myeloma, and the subsequent purchase of Onyx by Amgen. Previously, Dr. Love served as president, chief executive officer and chairman of Nuvelo, Inc., and as senior vice president, development, at Theravance, Inc. Dr. Love began his biotech career at Genentech in 1992, where he held several senior management positions in clinical science and product development, and ultimately as chairman of Genentech's Product Development Committee. As vice president, product development, Dr. Love oversaw the development strategy and execution leading to approvals of Rituxan®, Herceptin®, Xolair®, TNKase®, Raptiva® and Avastin®. Prior to Genentech, Dr. Love was a member of the Department of Cardiology at the Massachusetts General Hospital. Dr. Love currently serves on the boards of directors of Royalty Pharma and Structure Therapeutics. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.

CME credits: 1.00 Valid until: 12-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/nccn-guideline-updates-in-dlbcl/15181/ This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19

CME credits: 1.00 Valid until: 12-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/antibody-drug-conjugates-in-fl/15179/ This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19

CME credits: 1.00 Valid until: 12-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/bispecific-antibodies-in-fl/15178/ This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19

CME credits: 1.00 Valid until: 12-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/individualizing-frontline-treatment/15177/ This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19

CME credits: 1.00 Valid until: 12-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/application-of-data-from-the-echelon-1-trial/15176/ This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19

CME credits: 1.00 Valid until: 12-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/first-line-treatment-of-adults-with-classical-hodgkin-lymphoma/15175/ This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19

CME credits: 1.00 Valid until: 12-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/late-stage-bispecifics-and-adcs-in-dlbcl/15182/ This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19

CME credits: 1.00 Valid until: 12-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/patient-selection-for-adcs-in-first-line-dlbcl/15183/ This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19

CME credits: 1.00 Valid until: 12-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/clinical-implications-of-bispecific-antibodies-and-antibody-drug-conjugates-in-fl/15180/ This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19

I recently traveled to Seattle to visit my specialists. I saw my lung docs as well as a rheumatology specialist. Antisynthetase syndrome is rare enough that my local rheumatologist treats only me with the disease. There I learned a lot about Ig. For many of us IVIg and SCIg is a live-giving therapy. It has changed the course of my illnesses even though I have an adverse reaction to it. Those of us with autoimmune diseases are fighting our own bodies, in order to control that, doctors put us on drugs that suppress our immune systems. Naturally, that impacts our ability to fight disease and other external threats. In recent years, my chief complaint has been that being around people makes me sick. Even when those people aren't sick. In Ep 350 I talk about getting my Ig tested to see if I was mounting autoantibodies for the COVID vaccine. The rheumatologist in Seattle looked back at those labs from May and said my Ig numbers were too low. One's Ig numbers should not fall below 600. Mine were barely above 500. There are two ways to remedy this: give Ig (SCIg or IVIg) or reduce immunosuppression. For me, that means reducing my Rituxan. Here, 10 years into living with autoimmune disease I'd never heard of measuring my Ig levels, or learned about the 600 threshold, and that being on a heavy-hitting drug like mine, these levels should be monitored quarterly. That seemed like information worth sharing. Are you on chemotherapy or other strong immunosuppressive drugs? Do you get your Ig tested regularly? Did you know about the 600 threshold? Sound off! I'm Annette Leonard, speaker, coach, and sick person who believes that my illnesses do not define me. If health is the absence of disease and wellness is the presence of wholeness, then no matter what your disease status, we can work toward your wellness, your wholeness. Whether or not you are ever "healthy" on paper, you can be well. Join me and others on the path back to wholeness at AnnetteLeonard.com. Whether you are a person experiencing chronic illness or are someone who loves or serves people with chronic illness I have great resources here on this channel or on my website for you.

If you can avoid getting COVID, do. Here's a bit about what happened when I got COVID. Because of my lung disease I can't breathe through a N95 or KN5 mask. But, while wearing a cloth and surgical mask, I caught COVID from my sister-in-law. I'd just had treatment (Rituxan/chemo) about 10 days prior so my immune system was fully suppressed to keep me from fighting myself. We'd been having fires in the area so I thought perhaps my scratchy throat was due to the poor air quality. Then I got more tired. A negative COVID test made me feel hopeful that I wasn't sick but I coughed all night long. When I tested positive the following day, I knew I'd exposed her. For the first 24 hours, COVID felt like the worst flu I've ever had -- high fever, chills, extreme body aches, nausea/vomiting, terrible headache. The headache (in combination with my migraines) was extraordinary. Sleeping in 60-90 minute chunks because of coughing, congestion, mouth-breathing, and crippling fatigue. After sweating through the sheets on one side of the bed, I grew bone weary moving to the other side of our queen-sized bed. I'll continue to discuss how COVID played out in the coming days and weeks. Let me know if you have questions or tell me how you've been impacted by COVID with co-existing conditions. I'm Annette Leonard, speaker, coach, and sick person who believes that my illnesses do not define me. If health is the absence of disease and wellness is the presence of wholeness, then no matter what your disease status, we can work toward your wellness, your wholeness. Whether or not you are ever "healthy" on paper, you can be well. Join me and others on the path back to wholeness at AnnetteLeonard.com. Whether you are a person experiencing chronic illness or are someone who loves or serves people with chronic illness I have great resources here on this channel or on my website for you.

Sorry for my absence, my last video on YouTube was taken down. I received monoclonal antibodies. These are not the same as the antibodies given to people to treat COVID, but for COVID prevention. Monoclonal antibodies are given to folks for whom standard vaccines won't work or who are severely immune compromised. You may remember that on my last trip to Seattle I learned that while I have had 4 COVID vaccines/boosters -- I had almost no protection. My chemotherapy agent, Rituxan, keeps B cells from replicating/maturing. My community, Eugene/Springfield is about 235,000 people. We have one place administering these treatments and my wait was about a month to receive the treatment. Ours is being offered at a Hospital Infusion Center. I was given 4, 1.5ml vials of the Evusheld treatment in two injections, given in the rump. While it was quick to administer, I was kept for more than an hour to make sure that I didn't have any injection reaction, anaphylaxis, rash, etc. Not only did I not, in the coming days, I didn't even have the difficulties I've had with the vaccine -- like tenderness at the injection site, fever, flu-like symptoms, etc. The protection is similar to the vaccines in that it prevents the worst of disease and death but not great protection against the newest variants. Also, similarly, it needs to be readministered after 6 months. Are you eligible for monoclonal antibodies? Have you had them? What is your experience? I'm Annette Leonard, speaker, coach, and sick person who believes that my illnesses do not define me. If health is the absence of disease and wellness is the presence of wholeness, then no matter what your disease status, we can work toward your wellness, your wholeness. Whether or not you are ever "healthy" on paper, you can be well. Join me and others on the path back to wholeness at AnnetteLeonard.com. Whether you are a person experiencing chronic illness or are someone who loves or serves people with chronic illness I have great resources here on this channel or on my website for you.

Having seen my expert pulmonary team recently up in Seattle, my doctor and I do not see eye to eye. I'm so fortunate, as a person with such a rare disease to have such a competent doctor, who is well-suited to treat me. With this recent visit it was made plain to me that my most life-threatening disease will always be prioritized. This was a new perspective for me. I take Rituxan (a chemotherapy agent) to suppress my immune system and keep my autoimmune diseases in check. However, it suppresses me so thoroughly that I get sick from being around others who aren't even sick. Therefore, I've been reducing the frequency of my Rituxan treatments to try and balance the effects. My dose is based on research done on RA patients more than 25 years ago. My tests in Seattle showed that there was a slight change in my lungs - a bit more scarring. My doctor's response was to insist that I return to my original dose of Rituxan. It seems plain to me that the new scars in my lungs are due to my recent bout of pneumonia. I don't have the sense that my lung disease is reignited. Here's a time when I really disagree. It's my body, not his, and I must weigh the cost benefit analysis. Is it worth it to increase my dose again? What if my lung disease IS starting to kick up again? I am not giving YOU medical advice -- I'm not qualified to do so. However, for me, I'm not sure I'll follow doctor's orders. We have these opportunities as patients to consider whether our quality of life is worth the extra quantity a treatment may give us. What if going against doctor's orders costs us dearly? Have you ever disobeyed doctor's orders? I'm Annette Leonard, speaker, coach, and sick person who believes that my illnesses do not define me. If health is the absence of disease and wellness is the presence of wholeness, then no matter what your disease status, we can work toward your wellness, your wholeness. Whether or not you are ever "healthy" on paper, you can be well. Join me and others on the path back to wholeness at AnnetteLeonard.com. Whether you are a person experiencing chronic illness or are someone who loves or serves people with chronic illness I have great resources here on this channel or on my website for you. WIN A COPY OF ARLENE'S BOOK Here's how to enter: 1) Leave me a rating or review on whatever audio podcast platform you listen to. 2) Let me know you've done that by emailing me at hello@annetteleonard.com or leaving me a comment about it on YouTube so that you can be entered in to the drawing. If you have a preference about which book you'd like, let me know in your comment or email. (I'm also giving away a copy of Michael Murray's My Pain Body Solution) 3) If you'd like to be entered multiple times you can also post about one (or both of the books) and tag me on Instagram @theAnnetteLeonard including tag of either @arlenefaulk or #mypainbodysolution, for up to two additional entries. The drawing is planned for 6/30

What began as a severe skin rash for Patty Pittala became a diagnosis of B-cell non-Hodgkin lymphoma.  Thanks to a positive, proactive attitude, and a no-nonsense treatment regimen, Patty attained survivorship.  She enjoys a healthy lifestyle that includes her taking up kayaking.  This is her story.

I'm recently back from seeing my team of specialists up in Seattle. I go up to UW several times a year to consult about my lung disease. This trip I was able to consult with a rheumatologist who treats other patients with antisynthetase syndrome. As you know I take Rituxan (Rituximab, Ritux) as an infusion for my autoimmune disease. Part of how it works is it kills and keeps B cells from maturing. The COVID vaccine (and other MRNA vaccines) rely heavily on B cells to replicate and produce the autoantibodies that make the vaccines effective. While I've had 4 COVID vaccines at this point, I've been told to understand that they likely have limited effectiveness because of the Rituxan treatments I receive in an ongoing way. In Seattle, the consulting rheumatologist decided to test my blood for COVID antibodies to see what protection the vaccines have given me. I was warned that the labs might be confusing to understand and therefore, he said, "if you Spike Ig number is less than 1000," you have way too little protection and you should get monoclonal antibody treatment. When I read the labs the following day, my number was 5.7!!!! That number is so low, it looks like I've never had a vaccine much less four. I am, of course, a candidate for Evusheld, the monoclonal antibody treatment. Are you on an immune modifying drug? If so, get your doctor to test your antibodies? There are new ways to protect yourself. Have you had Evusheld? Are you on Rituxan and been taking COVID vaccines? Tell me about your experiences. Book giveaways: I'll be having a drawing to give away two books. One is "My Pain Body Solution," by Michael J Murray, (https://greenleafbookgroup.com/titles/my-pain-body-solution) the other is "Walking on Pins and Needles," by Arlene Faulk (https://www.bookcellarinc.com/walking-pins-and-needles). Here's how to enter: 1) Leave me a rating or review on whatever audio podcast platform you listen to. 2) Let me know you've done that by emailing me at hello@annetteleonard.com or leaving me a comment about it on YouTube so that you can be entered in to the drawing. If you have a preference about which book you'd like, let me know in your comment or email. 3) If you'd like to be entered multiple times you can also post about one (or both of the books) and tag me on Instagram @theAnnetteLeonard including tag of either @arlenefaulk or #mypainbodysolution, for up to two additional entries. The drawing is planned for 6/30 for Arlene Faulk's book and 7/5 for Mike Murray's.

I'm feeling crummy today! I've just received my 4th dose of vaccine. I'm eligible because of being severely immunosuppressed/immunocompromised. I'm on a number of meds to suppress my immune system, one of them is an IV drug called Rituxan. Rituxan works by killing and keeping B cells from maturing. This is a problem because B cells are the primary way that vaccines produce and "remember" the antibodies created by vaccines. There are numerous studies now demonstrating how ineffective the COVID vaccine is in people receiving Rituxan. One study said that it was "statistically insignificant for people to have received the vaccine"(or not) if on Rituxan, based on the fact that it gave no protection against the virus. Studies like these are incredibly disheartening. As a person with serious lung disease, with mask mandates lifted, I'm scared. We are all tired of this pandemic and it's demands upon us. I'm wearing this mask today because a member of my household was exposed to a sick coworker. When I venture out, I'm disheartened by how few people are choosing to wear masks now that they aren't required. Remember those shop signs from the 80's "No shirt. No shoes. No service."? Well, we're all wearing shirts and shoes! What's one more (small) piece of cloth? Our lives are all touched by immune compromised folks, a kid who has cancer, someone on dialysis, an elderly person, and because we have proven that masks radically reduce the spread of COVID, what a generous and easy way to care for all of us. Today, where we are on the brink of WWIII and we are thinking "What can I do?" "How can I make change?" You can wear a mask. If you are healthy and know others for whom masking is a choice, encourage them to do the same.

With a family history of prostate cancer, Max Schlueter wasn't surprised when he was diagnosed.  What did come as a surprise was his cancer metastasizing to hip and spine.  A treatment regimen combining Lupron and chemotherapy kept the cancer at bay; however, years later, the cancer returned years later attacking the nerve linings of his legs and feet, rendering him a paraplegic.  Between determination, his Buddhist faith and a stellar team of physician therapists, Max regained his ability to walk.  Now retired, he has returned to an active lifestyle of skiing, kayaking and mountain climbing.

Listen to a soundcast of the December 2 and 3, 2021, FDA approvals of Rituxan (rituximab) plus chemotherapy for pediatric cancer indications, and Keytruda (pembrolizumab) for adjuvant treatment of Stage IIB or IIC melanoma.

Multiple Sclerosis News Today's columnist, Jenn Powell, discusses a computer-based training program which has captured cognitive gains in pediatric MS patients. Multiple Sclerosis News Today's columnist, Jessie Ace reads for Jennifer Powell as she describes her journey with Rituxan and the side effects. ===================================== Treatment for Relapsing MS Progression | MAYZENT® (siponimod) Read about MAYZENT, a once daily pill that can significantly slow down disability progression in people with relapsing MS. See full prescribing & safety info. https://www.mayzent.com/?utm_source=changeinrms&utm_medium=vanityurl&utm_campaign=novartis_mayzent_2020&utm_content=soundcloud ===================================== Are you interested in learning more about multiple sclerosis? If so, please visit: https://multiplesclerosisnewstoday.com/ ===================================== To join in on conversations regarding multiple sclerosis, please visit: https://multiplesclerosisnewstoday.com/forums/

I will be discussing a 20-year-old girl with a 3 year history of multiple sclerosis treated with B cell suppressive therapy . She was prescribed two biological disease-modifying antirheumatic drug (DMARD).This article was written by Sjowall and colleagues in the journal Frontiers in Neurology. She was initially prescribed tocilizumab, marketed in the US as Actemra.   Tocilizumab is a monoclonal antibody blocks signals from IL-6 receptors them, is a monoclonal antibody against the interleukin-6 receptor. Tocilizumab can lower the ability of your immune system to fight infections.She was subsequently prescribed rituximab, sold under the brand name Rituxan, another B- cell treatment.She suffered for 6 months with knee arthritis and a persistent rash. Lyme disease was considered by dismissed at the Lyme disease tests were negative.She was finally treated 6 months after the fact with doxyc ycline. 1.         Sjowall J, Xirotagaros G, Anderson CD, Sjowall C, Dahle C. Case Report: Borrelia-DNA Revealed the Cause of Arthritis and Dermatitis During Treatment With Rituximab. Front Neurol. 2021;12:645298 .You can hear more about these cases through his blogs, social media, and YouTube. Sign up for our newsletter to keep up with these cases.How to Connect with Dr. Daniel Cameron:Check out his website: https://www.DanielCameronMD.com/Call his office: 914-666-4665Email him: DCameron@DanielCameronMD.com Send him a request:  https://danielcameronmd.com/contact-daniel-cameron-md/Like him on Instagram: https://www.instagram.com/drdanielcameron/Join his Facebook group: https://www.facebook.com/danielcameronmd/Follow him on Twitter: https://twitter.com/DrDanielCameronSign up for his newsletter: https://www.DanielCameronMD.com/Subscribe and ring the bell: https://www.youtube.com/user/danielcameronmd/ Leave a review on iTunes or wherever else you get your podcasts.We, of course, hope you’ll join the conversation, connect with us and other readers, ask questions, and share your insights. Dr. Cameron is a Lyme disease expert and the author "Inside Lyme: An expert's guide to the science of Lyme disease." He has been treating adolescents and adults for more than 30 years.Please remember that the advice given is general and not intended as specific advice as to any particular patient. If you require specific advice, then please seek that advice from an experienced professional.

We are continuing our conversation with Dr. Paula O'Connor and delving into the role of pharma in access to medicine and clinical trials. Dr. O'Connor goes over the safety measures in place to keep patients safe throughout a trial and how clinical trials can give access to novel drugs to patients who may not otherwise be able to afford them.About Dr. Paula O'ConnorDr. O'Connor is a hematologist oncologist with over 15 years of experience in biotech and drug development leading Clinical Development, Medical Affairs functions, managing people and teams, while helping to bring multiple products to the market.  Most recently, Dr. O'Connor led the US Medical Affairs function at Oncopeptides, Inc., helping them to commercialize their first product, a peptide drug conjugate. Earlier in her career, Dr. O'Connor led programs for novel biologics (Rituxan, Avastin), small molecules (Tarceva, Nexavar, rociletinib, Rubraca, and Talzenna), and biosimilars (Udenyca).Paula served as the Executive Vice President of Clinical Development at Coherus Biosciences; the Global Development Lead for Talzenna at Medivation through its acquisition by Pfizer; the Medical Affairs Lead for Rubraca and rociletinib at Clovis Oncology; the Joint Global Development Lead for Nexavar and Global Development Lead for Oprozomib at Onyx Pharmaceuticals through its acquisition by Amgen; and in roles of increasing responsibility at Genentech, Inc. through its acquisition by Roche.Paula obtained her medical degree from Stanford University; did her Medical residency at Massachusetts General Hospital, where she was the first African American Chief Resident in Internal Medicine; and did her Hematology-Oncology fellowship at the MGH/BWH/DFCI combined program.Outside of work, Paula is a parent, a tennis fan, and the owner of 2 burmese cats.--New Episodes every Tuesday, available wherever you get your podcasts! Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!Sign Up for our newsletter here or at 3BlackDocs.com  A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients. Learn more about Oncopeptides at https://www.oncopeptides.com/en Join the Conversation! Follow us on social media!3 Black Docsfacebook.com/3blackdocstwitter.com/3blackdocsinstagram.com/3blackdocsYouTube.com/3blackdocsDr. Karen Winkfieldfacebook.com/drwinkfieldtwitter.com/drwinkfieldinstagram.com/drwinkfieldDr. Zanetta Lamarfacebook.com/drzanettainstagram.com/drzanetta

We are so excited for this next episode with our special guest, Dr. Paula O'Connor! We talk about finding your path in medicine and all of the many opportunities there are to follow your passions within the medical field. Dr. O'Connor gave us so many gems development of career and development of self.About Dr. Paula O'ConnorDr. O'Connor is a hematologist oncologist with over 15 years of experience in biotech and drug development leading Clinical Development, Medical Affairs functions, managing people and teams, while helping to bring multiple products to the market.  Most recently, Dr. O'Connor led the US Medical Affairs function at Oncopeptides, Inc., helping them to commercialize their first product, a peptide drug conjugate. Earlier in her career, Dr. O'Connor led programs for novel biologics (Rituxan, Avastin), small molecules (Tarceva, Nexavar, rociletinib, Rubraca, and Talzenna), and biosimilars (Udenyca).Paula served as the Executive Vice President of Clinical Development at Coherus Biosciences; the Global Development Lead for Talzenna at Medivation through its acquisition by Pfizer; the Medical Affairs Lead for Rubraca and rociletinib at Clovis Oncology; the Joint Global Development Lead for Nexavar and Global Development Lead for Oprozomib at Onyx Pharmaceuticals through its acquisition by Amgen; and in roles of increasing responsibility at Genentech, Inc. through its acquisition by Roche.Paula obtained her medical degree from Stanford University; did her Medical residency at Massachusetts General Hospital, where she was the first African American Chief Resident in Internal Medicine; and did her Hematology-Oncology fellowship at the MGH/BWH/DFCI combined program.Outside of work, Paula is a parent, a tennis fan, and the owner of 2 burmese cats.--New Episodes every Tuesday, available wherever you get your podcasts! Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!Sign Up for our newsletter here or at 3BlackDocs.com  A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients. Learn more about Oncopeptides at https://www.oncopeptides.com/en Join the Conversation! Follow us on social media!3 Black Docsfacebook.com/3blackdocstwitter.com/3blackdocsinstagram.com/3blackdocsYouTube.com/3blackdocsDr. Karen Winkfieldfacebook.com/drwinkfieldtwitter.com/drwinkfieldinstagram.com/drwinkfieldDr. Zanetta Lamarfacebook.com/drzanettainstagram.com/drzanetta

Wegener's Vasculitis - that's what my Rheumatologist told me I had. It wasn't easy to hear, and it was more difficult to live with. In my first episode about my journey (see podcast episode 4 - My Journey with Wegener's Vasculitis Part 1) I shared onset and diagnosis. Today I share with you those next couple of years. The treatments. The side effects. The emotional turmoil. I put on 140lbs in a year. Do I break up with my boyfriend or sentence him to life with someone non-functional? How do I feel about freezing embryos? Taking a medication to deal with the side effects of a medication (ie: prednisone) It's not easy, but I want you to know you're not alone... I've been there too. I hope you find support, understanding and connection in my journey.

Today I talk with my good friend Nicole about her journey with Wegener's. Nicole is a Mom of two girls. She navigated onset of her disease with being a Mom of very tiny (her youngest was 18mo at onset!) humans. She is also a podcaster and entrepreneur. I am once again amazed by the similarities and differences in our journeys. You can find out more about Nicole below: Instagram: @SimplyWholeMoms Podcast: Simply Whole Moms Website: http://www.simplywholemoms.com Nicole has a 4 part series on her website about her journey if you are looking for more information.

In this episode of the “CURE Talks Cancer” podcast, we spoke with r. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, also known as WM.    WM is a rare, incurable disease. Its current standards of care available consist of Rituxan (rituximab), Imbruvica (ibrutinib) combinations or monotherapy in the first- and second-line setting. However, there are no treatments currently approved for the third line.   Chanan-Khan discussed these options, as well as a novel agent, CLR 131, that is being evaluated in a phase 2 study. 

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Matthew Davids about the results of a clinical trial that assessed the addition of Copiktra (duvelisib) to fludarabine, cyclophosphamide and Rituxan (rituximab) in the frontline setting for patients with chronic lymphocytic leukemia (CLL) aged 65 years and younger. Davids, director of clinical research in the Lymphoma Program at Dana-Farber Cancer Institute in Boston, also provides insight into the current CLL landscape and discusses what he refers to as a swing in the pendulum of CLL research over the last 10 years, and how that pendulum swing has created a slight gap for the assessment of younger patients with the disease.  “As the novel agents have come of age here in the last decade, that as a field, we've gotten better at kind of shifting the studies into older patients,” Davids explained in an interview with CURE®. “… One kind of gap that I can see right now in the field is that because the pendulum has swung, I think appropriately toward the older population in terms of the trials, we actually do seem to have fewer trials kind of focused on the young fit patients compared to the old days. And so that is an area I think of interest for sure is the novel agent-based approaches in the young patients.” 

When your body starts to fight you, it can be the hardest and scariest journey of them all. We've all heard people say, "At least you have your health." When you're body is trying to kill you, there is no where safe to hide. Vasculitis is a particularly difficult disease to diagnose. It presents in several different forms. In today's episode I talk about just the first couple of months of being sick, of receiving my diagnosis, and the first treatment we tried. Look fore more episodes soon about my personal journey, as well as other's stories about the onset of their diseases! Please visit: The Vasculitis Patient Powered Network (vpprn.org) for more information on ALL forms of Vasculitis, as well as information about different studies being done. Most importantly, if you have any form of Vasculitis, PLEASE sign up and answer the simple online forms that give researchers so much more information. Our diseases are RARE and we need all the help we can get. We're in this together, help us fight and save lives TODAY!

Diagnosed with non-Hodgkin's lymphoma in January 2015, Brandon LaGreca used an integrative protocol to put it into complete remission in eight months. For complete show notes, visit http://youcuredwhat.com/podcast/brandon[0:55] Joe gives a brief overview and biography intro for Brandon LaGreca. [2:20] Brandon gives the background on his diagnosis. He was 34 and went to the hospital with horrible abdominal pain in January 2015. It turned out he had a 4-inch abdominal tumor, causing a bowel obstruction. It turned out to be stage 4 non-Hodgkin's lymphoma. [4:25] Non-Hodgkin's lymphoma is considered incurable in the conventional paradigm. [5:10] What went through Brandon's mind when he got this diagnosis? [6:30] One part of Brandon went into shock, but the other part went into his clinical problem-solving mindset. [8:00] Brandon is glad his oncologist didn't give a specific prognosis or do any "medical hexing". [9:20] Brandon asked his oncologist: if Brandon made it to 5 years without a recurrence, would there be something different about him? The oncologist said yes. It has now been 5 years. [10:30] Brandon already wrote the book Cancer and EMF Radiation, and he is now working on a new book Cancer, Stress, and Mindset. [12:00] After his diagnosis, Brandon decided to see what conventional oncology had to offer him. [13:30] Brandon was offered R-CHOP (Rituxanimmunotherapy drug plus a chemotherapy cocktail). Brandon didn't want chemo so he reached out to his holistic medicine colleagues and friends. [14:35] Brandon decided to take Rituxan for immunotherapy but opt out of chemo, and his oncologist agreed. Brandon would put together an integrative protocol in combination with the Rituxan. [15:50] At first, Brandon did four sessions of Rituxan once a week for four weeks to reduce tumor burden. After that, he did one session every two months. [17:00] After the first four sessions (to allow the effects of the drug to initially be isolated), Brandon kicked his integrative protocol into high gear. This protocol included supplements, homeopathics, and emotional and spiritual support. [18:20] Brandon finds that one of the big benefits of his integrative protocol was that after getting healthy, he could continue the practices (unlike chemotherapy, which can only be done temporarily). [19:05] The first category of his integrative protocol was emotional/spiritual/mindset. One key to this was asking himself how he would be a better person on the other side of the cancer diagnosis. [22:25] Another category was detoxification via heavy metals chelation and sauna work. [25:45] Brandon followed the work of Dr. Nick Gonzalez and Dr. William Donald Kelley who focused on metabolic type diets. In Brandon's case, he followed the parasympathetic diet with a good amount of animal fats and proteins. He also ate a colorful array of vegetables and fruits. No processed foods. [28:30] Brandon also added in different herbs and nutraceuticals. Some examples are medicinal mushrooms, turmeric, hemp, and green tea. [29:40] Brandon was also getting a homeopathic injection of mistletoe several times a week. This is based off the work of Rudolf Steiner. [33:30] Brandon also incorporated different forms of meditation. One of these is a moving meditation called qigong. [36:40] For diet, Brandon recommends the Weston A. Price Foundation for giving an umbrella of what nutrient-dense whole foods are and what good dietary principles are. [40:20] What challenges did Brandon face on his journey to healing? Gastrointestinal distress issues have been challenging. [46:30] Does Brandon consider himself cured of non-Hodgkin's lymphoma? [48:00] Brandon recommends the book Radical Remission. [50:35] Now that he's improved his health, what's one thing Brandon enjoys doing that he couldn't do before? [52:50] What recommended resources does Brandon have for others who want to learn more about his approach to healing from cancer? [56:00] Brandon talks a bit about electromagnetic fields (EMFs) and their role as a carcinogen.

How do I feel after the infusion? What are the benefits? What does the muscle wasting feel like? With chronic pain and chronic conditions, any bit that we can carve out or reclaim is giant territory that is not ceded to our disease. My infusion gives me several months of positive effects. We've gauged the time of my infusions based on when effects start to wear off. Consider these autoimmune diseases without the benefits of modern medicine. How fortunate we are to live during a time when there are these options. Have you tried infusing meds? Have they worked for you?

How do I get my Rituxan treatments? How does prednisone impact getting an infusion? What are premeds and why are they important to the process? Because I am at a rheumatology clinic, I am with other autoimmune patients during my infusion. That is also a therapeutic part of the treatment. We learn from each other and share war stories, share tips, share the burden of living with these illnesses.

Autoimmune disease is our body fighting our self. Without Ig products I needed other meds online. My doctors decided on Rituxan/Rituximab. During the 2.5 years of IVIg/SCIg I didn't catch colds and flus. However, since being off IVIg, I catch any and every virus that's circulating. That was a tremendous benefit. The difference is remarkable. Our bodies cannot rally a defense on immunosuppressing drugs. This is so that our bodies are kept in a state that lessens the attack we are mounting on ourselves. Rituxan keeps my B cells from maturing. Have you taken an infusing med or been on a biologic? Leave me a comment and tell me how that's gone.

How can chemotherapy agents help halt the advance of autoimmune disease? Some examples: methotrexate, and Rituximab In the case of Rituxan, the agent keeps the body's B cells from maturing. This reduces how I fight infections and viruses but also how much I fight my own tissues. Thankfully, we've generated some creative ways to stave off how to keep our bodies from attacking ourselves. Why are autoimmune diseases on the rise? There is a strong hypothesis in "The Lady's Handbook for her Mysterious Illness." The book whose author I interviewed in episodes 206-208. What meds do you take to manage your autoimmune disease? Is it helping keep your disease in check?

- Jackie was first diagnosed with RA in 2016 and the pain was devastating - After a difficult diagnosing process she started methotrexate and Enbrel, and after 8 months things weren't changed much - In the next 6 months she went through some cumbersome insurance mechanisms and eventually was eligible for Rituxan - She started Rituxan infusions while dropping Enbrel and keeping methotrexate, and after a couple of months she was feeling better - In the meantime she found the Paddison Program while searching through the internet, and decided to start with it as well - Then her insurance company refused to support other infusions of Rituxan and she decided to proceed with the Program anyway - Jackie is now only on a minimal dose of Methotrexate and has added Bikram yoga to progress her health even further!

I was due for my Rituxan infusion, my primary multiple sclerosis (MS) medication. I called a week ahead. I needed to get bloodwork at a lab and approval from the insurance company. The bloodwork was no problem, but the approvals were difficult. I had to be persistent. Before I knew it, I was a month and a half late.

Interesting trial this week evaluating a fixed schedule of rituximab vs. a tailored approach to therapy. See you all at ACR this week! 

This week we discuss the pivotal RAVE trial in all it's rituxan justifying glory.  I've also added a handy Box link with all of the papers I've discussed, so check it out if you'd like to follow along! Link here.

Prior to Aventria, David held several commercial leadership roles, including Head of Oncology Marketing at Genentech and VP Strategic Marketing at Schering AG, specializing in commercializing oncology and specialty products. He was also instrumental in the commercialization of Taxotere, Fludara, Herceptin, and Rituxan. Paul has extensive experience leading successful market access commercialization strategies of specialty pharmaceuticals throughout their life cycles, including several landmark oncology products and other specialty therapeutics. Paul is a former Vice President of Payer Marketing with Bayer and former Vice President and Head of Oncology Managed Markets and Market Access at Novartis Pharmaceuticals. He is an RPh and a graduate of Rutgers University's Ernest Mario College of Pharmacy. 00:00 The trends affecting market access to oncology. 02:00 Innovations in oncology. 02:20 Immuno-oncology. 03:50 How treatment has improved with these oncology innovations. 05:45 The implications of patients getting access to these new treatment options. 07:20 Answering 3 questions around these oncology innovations. 10:05 Outcomes-based contracts and biomarker testing. 11:30 Risk-based contracts. 12:15 Indication-based pricing 14:45 “How do we make access to novel specialty drugs more affordable for the actual patient.” - Paul Pochtar 17:50 How various biomarkers fit in together. 18:15 Determining what biomarkers are relevant. 19:00 Pathways and guidelines being derived from Real World Evidence. 20:45 “There's no standardized approach.” - David Guy 23:40 How a pathway gets used. 29:35 Alternative payment models. 30:15 “As we look for a solution, it's not one entity that has the answer.” - Paul 30:45 Innovation, cost challenge, decision-making process. 32:38 “The elephant in the room is the co-pay burdens.” - David 32:57 Why is a co-pay applicable for a cancer patient? 33:33 Andrew Schorr of Patient Power - EP145.

What's The Matter With Me? Podcast Episode 30 My name is John, I'm 38 years old, husband and father of two, small business owner, radio DJ, podcaster, and I have multiple sclerosis.  I made this podcast to share what I'm going through. Disabled entrepreneur Episode 30 of the What's The Matter With Me? podcast revolves around promoting my brand at a trade show as a disabled entrepreneur with MS. It was really fun and a major step forward for my business. Check out the episode for more. Transcript: Welcome to the What's The Matter With Me? Podcast Episode 30: "Disabled Entrepreneur." My name is John. I'm 38 years old, husband and father of two, small business owner, radio DJ, podcaster. And I have MS. I made this podcast to share what I'm going through. Recap last episode. I was talking about shoelaces, and some listeners wrote me back on the What's The Matter With Me? Podcast Facebook page. That was cool. Thanks for hitting me up. I'm going to check out your suggestions. And then steroids. I took my MS drug Rituxan, and I had to take steroids. We had a little discussion about MS drug fatality risk. I talked about that I was going to the Winter Fancy Food Show. We'll talk about it in a minute. It was cool. And then I played episode 3, the throwback episode. Check whatsthematterwithme.org. I went to the Winter Fancy Food Show yesterday. It was a massive deal for Hoppin Hot Sauce first and foremost. But it was a big physical challenge for me as a person with MS. I had a lot of anxiety about it, leading up to it. I was also just doing a lot of work, so it was pretty stressful. I'm glad it's over. I'm still decompressing. It was just yesterday. In fact, I'm kind of still in work mode. I'm sending invoices and filing stuff and getting ready to reach out again. So I guess it never ends, but Winter Fancy Food Show was great. We were set up in a row of young entrepreneurs. The guy on the right to me made a bunch of different kinds of hummus and interesting … he was Persian, interesting Persian products. The partners on the other side were a man and a woman, and they made cookies out of tofu production secondary stream products. Which means stuff that's usually a byproduct or a throwaway product. They used … they made it into flour, like some residue from soybean into flour. They wanted to make tortillas and all kinds of other bread products. But they make at this time cookies. That was cool to be next to them. There were a lot of attendees walking by, thousands, throughout the day. We were in between Moscone North and South, kind of at the entrance of the hall in this kind of corridor, outside the elevator. Anyway, it had lots of people. It was a good location, because many people passed by and you could get them to sample the products. And so I'm a natural hawker. I'm like, "Hey, you." Make eyes at people. They love me. I say stupid things. I'm great if you like a stupid hawker. I'm bad if you're, like, wanting a highbrow afternoon. I'm not going to give it to you. I'm like to people … I'm like, "Hey, you know. I think you should probably try Hoppin Hot Sauce. It'll change you." I just say … I think other people don't say weird enough stuff, or they say boring thing. "Would you like to try?" I didn't want to do that. I mean, how could I say that? I'm not that kind of guy. "Would you like to try a sample? Sample?" No, no. No. I'm just like, "Hoppin Hot Sauce will change you." You know what I mean? If I don't get them the first time, I'll just be a little firmer. I didn't hector or harangue anyone. I made a note beforehand, "Do not harass anyone walking by the way you know that you are just liable to do. No potshots. Highbrow only. Keep it clean." Yeah, I did it. It was good. There were some folks there, though. You know what I mean? A big old conference in San Francisco has some people looking of some type of way at the conference. It is great. There was a guy with crabs on his pants.

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: AstraZeneca, Amgen, AIFA, EMA, FDA, Novartis.Persone: Enrica Bucchioni (AstraZeneca), Pablo Panella (AstraZeneca), Andrea Mantovani (Amgen), André Dahinden (Amgen), Paola Testori Coggi (AIFA), Mario Melazzini (AIFA), Carmine Pinto (AIOM).Nuove terapie: avelumab, midostaurina, Venclexta, Rituxan.Patologie: carcinoma a cellule di Merkel, leucemia mieloide acuta, sindrome di Tourette, leucemia linfatica cronica.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: AstraZeneca, Amgen, AIFA, EMA, FDA, Novartis.Persone: Enrica Bucchioni (AstraZeneca), Pablo Panella (AstraZeneca), Andrea Mantovani (Amgen), André Dahinden (Amgen), Paola Testori Coggi (AIFA), Mario Melazzini (AIFA), Carmine Pinto (AIOM).Nuove terapie: avelumab, midostaurina, Venclexta, Rituxan.Patologie: carcinoma a cellule di Merkel, leucemia mieloide acuta, sindrome di Tourette, leucemia linfatica cronica.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

We left, we went to a beautiful wedding in Boonville. They had an oyster bar and I ate there with a couple friends. That was a really nice activity. The food was wonderful. The wedding was beautiful. One of the brides wore a leather wedding dress made by Valentino. The wedding had caviar on a runcible spoon and a fine Italian wine at the meal. Begin Transcript What's the Matter With Me? Episode 9, "Wedding In Boonville." Yeah, it's What's the Matter With Me? Episode 9! My name is John. I'm 38 years old. I have MS, I made this podcast to share what I'm going through. Fundraiser Script Information Orangutan Couch Potato OneCouch Potato TwoInformation Orangutan The sound of a live performance. They're watching it on a stream, on a computer. Couch Potato One: I think this KFJC live stream is melting my face off.Couch Potato Two: I am taking serious damage. Computer error. Coach Potato One: Oh, no. Aww, something's wrong with our computer and we need to fix it.Couch Potato Two: We need to call the IT person.Couch Potato One: Get the phone book. Look it up. What does IT stand for?Couch Potato Two: Information something or other. Here it is, Information Orangutan. Phone call. Dialing. Information Orangutan: Hello, Information Orangutan... Information Orangutan, you rang-a-dang-dang, dang. Chicken sounds and wailing off-mic, in the background, like Screamin' Jay Hawkins, and also Harry and the Hendersons. Couch Potato Two: Hello our computer is malfunctioning. Lots of errors and "does not compute."Information Orangutan: Be right there. The sound of a time and space portal opening. The Information Orangutan steps out of it into the couch potatoes' living room. Information Orangutan: Information Orangutan, you rang-a-dang-dang? Off-mic chicken sounds and gibberish wailing. Couch Potato One: Our computers aren't working.Couch Potato Two: Our computers aren't working and we need you to fix them! More chicken sounds, and wailing. Couch Potato Two: Dude, I think he's not going to fix our computers. I think he's just an orangutan.Couch Potato One. We went about this all wrong. We should have called (650) 941-6800 to donate to the KFJC fundraiser, and nothing bad would ever happen to us after that.Couch Potato Two, If we ever get the internet working again, I will go to KFJC.org and donate online. The Information Orangutan's unintelligible holler … All right. So, that was a script. I guess you might have guessed that was a script I'm writing or that I wrote. Fundraiser season at KFJC, the radio station that I have a show on, on Thursdays, that's coming up and so we need advertisements. I guess that was me reading this script I wrote, called Information Orangutan. I had this idea- I just, literally had the phrase in my mind "Information Orangutan, you rang-a-dang-dang?" And so I wrote that just so I could use it. It'll be interesting. Supposedly, at the KFJC staff meeting tonight, we are meant to record that, so we'll see. We'll see how it ends up. I mean it's kind of long, it took three minutes. What's the Matter With Me? Episode 9, "Wedding in Boonville", welcome. Thank you for listening. Thank you for joining me. Recap of "Big Week." I went to the barber shop. I had my annual checkup with the doctor. I have to make a correction. I said "cerebrum"… I should have said cerebrum. I said "cerebellum" and the cerebellum is underneath the cerebrum. I meant the cerebrum, the big brainy part of your brain, not the brain stem or interior brain. The cerebellum. Rituxan infusion So anyway, I did that. I had my radio show, I talked about poverty with my therapist. I went to a birthday party. I got my Rituxan infusion, in Stanford on Friday for four hours. I got pumped full of steroids and Benadryl and Rituxan. So I sat there and slept, this odd state of being totally pumped up and also sleeping. Family in Santa Rosa

Elayne Marks: is the Tamarac, FL chapter president of “City of Hope”, a medical drug research center and a National Cancer Institute- Designated Comprehensive Cancer Center located Los Angeles, CA. Research conducted at City of Hope has led to significant advances in modern medicine, making a difference in the lives of people with cancer, diabetes and other serious illnesses. Their research has created the development of the first synthetic human insulin, human growth hormone and the technology behind the widely-used cancer-fighting drugs Herceptin, Rituxan and Avastin. Their mission is to transform the future of health care by providing outstanding care, conducting innovative research, treatment protocols, and vital education programs focused on eliminating these diseases, giving people the chance to live longer, better lives. “Power of Knowledge Saves Lives!” Website: www.cityofhope.org Email:NewPatientreferral@coh.org.Phone: 800-423-7119 or 626-256-HOPE (4673). New Patient Services: 800-826-4673Facebook: CityofHope

Elayne Marks: is the Tamarac, FL chapter president of “City of Hope”, a medical drug research center and a National Cancer Institute- Designated Comprehensive Cancer Center located Los Angeles, CA. Research conducted at City of Hope has led to significant advances in modern medicine, making a difference in the lives of people with cancer, diabetes and other serious illnesses. Their research has created the development of the first synthetic human insulin, human growth hormone and the technology behind the widely-used cancer-fighting drugs Herceptin, Rituxan and Avastin. Their mission is to transform the future of health care by providing outstanding care, conducting innovative research, treatment protocols, and vital education programs focused on eliminating these diseases, giving people the chance to live longer, better lives. “Power of Knowledge Saves Lives!” Website: www.cityofhope.org Email:NewPatientreferral@coh.org. Phone: 800-423-7119 or 626-256-HOPE (4673). New Patient Services: 800-826-4673 Facebook: CityofHope

Currently SVP of Oncology and Specialty Market Programs at Aventria Health Group.  Formerly was  CCO at Favrille, VP Strategic Marketing at Schering AG and Head of Oncology Marketing at Genentech; was instrumental in the commercialization of Taxotere, Fludara, Herceptin, and Rituxan 00:00 New Oncology Breakthroughs. 02:35 Extending survival time to stabilizing curves that could extend to future cures. 03:50 The average cost of a new Oncology product is more than $100,000 for annual cost of treatment. 04:15 “The question is how, as a Health System, we're going to be able to manage that.” 04:30 What Payers are doing to afford these new Oncology Breakthroughs. 04:50 Creating Pathways and Incentivizing Providers to use these Pathways. 05:20 The difference between a Pharmacy Benefit and a Medical Benefit. 05:50 “Buy and Bill.” 06:30 The potential for Providers to make a significant portion of their income from purchasing more expensive products. 07:00 Medicare's adopted average selling price & demonstration project for Buy and Bill. 07:50 How Bundled Payments is affecting the cost of Oncology. 09:00 The Oncology Care Model and shifting to an Episodic Care Model. 09:50 The Evidence-Based approach to treating patients. 10:15 NCCN Guidelines. 11:00 “As long as the Pathways reflect the Gold Standard.” 11:50 Payers are trying to get more consistent care, rather than trying to limit the cost of care. 12:15 Laws requiring Payers to cover Oncology treatment. 14:00 The importance for Manufacturers to communicate and demonstrate the value of their medication. 15:00 Creating a Step Approach. 16:20 Change in the future allowing Medicare negotiate prices with manufacturers. 17:50 David's advice for Pharmaceutical manufacturers. 18:15 Value-Based Contracting. 18:40 Risk-Sharing Program. 19:20 Paying by the Pill vs. Paying by the Value Medication Delivers. 19:40 A more Value-Based Reimbursement system. 20:00 You can find out more at AventriaHealth.com.

Dr Prockop talks to ecancertv at AACR 2015 about how patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was not responding to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called Epstein-Barr virus– specific cytotoxic T lymphocyte (EBV-CTL) therapy.

Today in FirstWord:

Today in FirstWord: